← Back to Screener
Pasithea Therapeutics Corp. Warrants (KTTAW)
Price$0.00
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (4W)-9.64%
VGM Score34.26
All Metrics
Price vs S&P 500 (YTD)-65.07%
10-Day Avg Trading Volume0.02M
3-Month Avg Trading Volume0.04M
52-Week High$0.12
13-Week Price Return-80.70%
3-Month Return Std Dev576.09%
Year-to-Date Return-48.94%
5-Day Price Return56.52%
Month-to-Date Return-2.70%
Price vs S&P 500 (13W)-91.27%
Beta1.24x
52-Week Low$0.00
mGradeD
vgmGradeD
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KTTAWPasithea Therapeutics Corp. Warrants | — | — | D | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Pasithea Therapeutics is a biotechnology company developing treatments for central nervous system disorders, RASopathies, and select cancers. Its pipeline targets neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, and schizophrenia, with lead candidates including PAS-004 (a MEK1/2 inhibitor), PAS-003 (a monoclonal antibody), and PAS-001.